Nucleic acid sequences showing enhanced expression in benign neuroblastoma compared with acritical human neuroblastoma

• US 7,087,383 B2
• Filed: 03/02/2001
• Issued: 08/08/2006
• Est. Priority Date: 03/07/2000
• Status: Expired due to Term

• Current Assignee: Chiba-Prefecture, Hisamitsu Pharmaceutical Company Incorporated
• Original Assignee: Chiba-Perfecture, Hisamitsu Pharmaceutical Company Incorporated
• Inventors: Nakagawara, Akira
• Primary Examiner(s): Horlick, Kenneth R.
• Application Number:
  US10/220,891
• Publication Number:
  US 20030207286A1
• Time in Patent Office: 1,985 Days
• Field of Search: 435/6, 536/23.5, 536/24.31, 536/24.33
• US Class Current: 435/6.14
• CPC Class Codes: C07K 14/47 from mammals

Abstract

There are disclosed a nucleic acid which is derived from the gene expressed in human neuroblastoma, and which comprises any sequence selected from the group consisting of the nucleic acid sequences set forth SEQ ID NO:1 to NO:104 in the Sequence Listing, or its complementary nucleic acid; a fragment of the nucleic acid; their use as probes or primers; and the diagnosis of neuroblastoma prognosis using any of the foregoings.

Claims

1. An isolated nucleic acid comprising a sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:

3, SEQ ID NO;

5, SEQ ID NO;

9, SEQ ID NO;

19, SEQ ID NO;

22, SEQ ID NO;

32, SEQ ID NO;

40, SEQ ID NO;

55, SEQ ID NO;

56 and SEQ ID NO;

74, in the Sequence Listing or a complementary nucleic acid thereof.

2. The nucleic acid according to claim 1, wherein the nucleic acid is DNA.

3. The nucleic acid according to claim 1, wherein the nucleic acid is derived from a gene expressed in human neuroblastoma.

5. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

3 in the Sequence Listing.

6. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

5 in the Sequence Listing.

7. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

9 in the Sequence Listing.

8. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

19 in the Sequence Listing.

9. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

22 in the Sequence Listing.

10. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

32 in the Sequence Listing.

11. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

40 in the Sequence Listing.

12. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

55 in the Sequence Listing.

13. The nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

56 in the Sequence Listing.

14. The isolated nucleic acid according to claim 1, wherein the nucleic acid sequence is SEQ ID NO:

74 in the Sequence Listing.

4. A method of diagnosising the prognosis of human neuroblastoma, said method comprising

extracting a neuroblastoma specimen from a subject;

detecting at least one nucleic acid in the specimen, the nucleic acid comprising a sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO;

3, SEQ ID NO;

5, SEQ ID NO;

9, SEQ ID NO;

19, SEQ ID NO;

22, SEQ ID NO;

32, SEQ ID NO;

40, SEQ ID NO;

55, SEQ ID NO;

56 and SEQ ID NO;

74, in the Sequence Listing or a complementary nucleic acid thereof; and

diagnosing the prognosis of the human neuroblastoma as favorable if said nucleic acid is detected.